British pharmaceutical giant GSK is conducting a large-scale study to determine whether its best-selling shingles vaccine, Shingrix, may reduce the risk of dementia. The study, announced on Tuesday, will analyze health data from over 1.4 million older adults in the UK, aged 65 to 66, some of whom have received the vaccine while others have not. At present, Shingrix is used to prevent herpes zoster (shingles), a painful skin rash caused by the varicella-zoster virus.GSK’s chief scientific officer, Tony Wood, highlighted that the study leverages a unique dataset from the UK's National Health Service (NHS). A recent adjustment in the country’s shingles immunization program has effectively created a naturally randomized trial. Prior to 2023, the vaccine was available only to individuals aged 70 and older. However, when the program was expanded, only those turning 65 became immediately eligible, while those already 66 had to wait until they turned 70. This unexpected division allowed researchers to compare two distinct patient groups without the need for a costly, traditional clinical trial.The study will track participants until they reach the age of 70, taking into account other medical conditions and factors that could influence dementia risk. Previous research has suggested a potential link between shingles vaccination and a lower risk of dementia, though it has not yet been proven to be causal. If the findings confirm a protective effect against dementia, the company may engage with regulatory authorities to explore expanding the approved uses of Shingrix.Is There A Vaccine For Dementia?While there's no vaccine currently approved to prevent or cure dementia or any of its forms, like Alzheimer's, research is ongoing into developing vaccines that target specific proteins involved in the disease process, like amyloid plaques and tau tangles. Apart from vaccines that prevent shringles, jabs to protect an individual against tetanus and diphtheria, with or without pertussis vaccine (Tdap/Td), and the vaccine for pneumococcus are also being studied as a probable demetia vaccine.How Prevelent Is Dementia?Currently more than 55 million people have dementia worldwide, over 60% of whom live in low- and middle-income countries. Every year, there are nearly 10 million new cases. Dementia is an umbrella term to describe diseases that cause people to lose their cognitive functions. These diseases gradually progress decreasing the ability for someone to function in daily life and take care of themselves. There are some medications used to delay the onset of it and to manage it. People can reduce the chances of developing it by following a healthy diet and lifestyle.